Orthopedic Board Review: Bone Tumors & Osteochondromas

Comprehensive Introduction and Patho-Epidemiology

Orthopedic oncology demands a rigorous understanding of both benign and malignant osseous lesions, with osteochondromas representing the most frequently encountered benign bone tumors in clinical practice. As a cornerstone of orthopedic board examinations, the conceptual mastery of bone tumors—specifically osteochondromas and their syndromic counterpart, Multiple Hereditary Exostoses (MHE)—is non-negotiable for the practicing orthopedic surgeon. An osteochondroma, or osteocartilaginous exostosis, is fundamentally a developmental hamartoma rather than a true neoplasm. It arises from an aberrant herniation of the physeal growth plate through the periosteal bone cuff (the perichondrial ring of LaCroix). This displaced fragment of cartilage continues to undergo endochondral ossification, resulting in a bony protuberance capped by hyaline cartilage that grows in tandem with the patient's skeletal development and typically ceases growth upon physeal closure.

The patho-epidemiology of these lesions is distinctly bifurcated into solitary osteochondromas and the autosomal dominant condition known as Multiple Hereditary Exostoses (MHE). Solitary osteochondromas account for approximately 35% of all benign bone tumors and 8% of all bone tumors overall. They are predominantly discovered incidentally in the first or second decades of life, with a slight male predilection. The defining radiographic and histopathologic hallmark of an osteochondroma is the direct continuity of its cortical and medullary bone with the host bone. This medullary continuity is the sine qua non for diagnosis, differentiating it from other surface lesions such as parosteal osteosarcoma or periosteal chondroma. The cartilage cap mimics a normal growth plate, complete with resting, proliferating, and hypertrophic zones, though often less organized.

In stark contrast, Multiple Hereditary Exostoses is a complex genetic disorder with an estimated prevalence of 1 in 50,000. MHE is driven by loss-of-function mutations in the EXT1 (chromosome 8q24) or EXT2 (chromosome 11p11-12) genes. These genes encode critical glycosyltransferases responsible for the biosynthesis of heparan sulfate. A deficiency in heparan sulfate disrupts the normal diffusion and signaling gradients of key morphogens in the growth plate, most notably Indian hedgehog (Ihh) and Parathyroid Hormone-related Protein (PTHrP). This disruption leads to premature differentiation of chondrocytes and the formation of multiple exostoses. Patients with EXT1 mutations generally present with a more severe clinical phenotype, characterized by a higher burden of lesions, more profound skeletal deformities, and a statistically higher risk of malignant transformation compared to those with EXT2 mutations.

The most critical clinical concern for any patient presenting with an osteochondroma is the risk of malignant transformation into a secondary peripheral chondrosarcoma. For a solitary osteochondroma, this risk is exceptionally low, universally cited in orthopedic literature and board reviews as less than 1%. However, in the setting of MHE, the cumulative lifetime risk of malignant transformation escalates significantly to approximately 1% to 5%. Transformation typically occurs in adulthood, well after skeletal maturity. The classic clinical red flags for malignant degeneration include a sudden onset of pain, a new palpable mass, or resumed growth of a previously stable lesion in a skeletally mature patient. Advanced imaging, specifically T2-weighted magnetic resonance imaging (MRI), is paramount in these scenarios; a cartilage cap thickness exceeding 1.5 to 2.0 centimeters in an adult is highly suspicious for secondary chondrosarcoma and warrants immediate oncologic staging and wide surgical resection.

Detailed Surgical Anatomy and Biomechanics

The anatomical distribution of osteochondromas is dictated by the sites of most rapid endochondral ossification, specifically the metaphyses of the long bones in the appendicular skeleton. The distal femur, proximal tibia, and proximal humerus are the most frequently affected sites, collectively accounting for over 50% of all lesions. Morphologically, osteochondromas are classified as either pedunculated (having a narrow stalk) or sessile (having a broad-based attachment). Pedunculated lesions characteristically point away from the adjacent joint, a phenomenon driven by the mechanical forces of overlying tendons and muscles acting upon the growing cartilage cap. Sessile lesions, conversely, cause more profound metaphyseal widening and remodeling, often leading to more complex surgical anatomy and a higher likelihood of impinging upon adjacent structures.

The local surgical anatomy is profoundly influenced by the presence of the exostosis, which displaces normal neurovascular and musculotendinous structures. A unique anatomical feature of osteochondromas is the frequent formation of an overlying adventitial bursa, termed an exostosis bursa. This structure develops in response to the chronic friction generated by muscles or tendons gliding over the bony prominence. While this bursa serves a protective mechanical function, it can become inflamed, hemorrhagic, or even infected, leading to acute pain that mimics malignant transformation. Furthermore, the bursa may contain loose cartilaginous bodies that have detached from the cap, which can calcify and complicate the radiographic picture. During surgical resection, the surgeon must be acutely aware of this bursa, as its incomplete removal can lead to persistent postoperative pain or recurrence of bursitis.

Neurovascular proximity is a paramount biomechanical and surgical consideration. Lesions originating from the medial aspect of the distal femur can impinge upon the superficial femoral artery or vein within the adductor canal, occasionally resulting in pseudoaneurysm formation, arterial thrombosis, or claudication. Similarly, osteochondromas of the proximal fibula pose a direct mechanical threat to the common peroneal nerve. As the tumor expands, it can stretch the nerve against the fibular neck, leading to foot drop and paresthesias. In the upper extremity, proximal humeral lesions can compress elements of the brachial plexus or axillary vessels. The biomechanical tethering of these structures requires meticulous pre-operative planning and often dictates extensile surgical exposures to achieve proximal and distal control of critical vessels and nerves prior to addressing the osseous lesion.

In patients with MHE, the biomechanical consequences extend far beyond localized impingement, manifesting as severe, progressive skeletal deformities. The presence of multiple lesions disrupts normal physeal growth, leading to limb length discrepancies and angular deformities. The forearm and lower leg are particularly vulnerable due to the paired bone anatomy. In the forearm, exostoses often cause disproportionate retardation of ulnar growth, resulting in ulnar shortening, secondary radial bowing, and eventual subluxation or dislocation of the radiocapitellar joint (Madelung-like deformity). In the lower extremity, proximal tibial and distal femoral lesions can induce valgus deformities, while distal fibular lesions can lead to valgus ankle instability. The surgical management of these patients is highly complex, often requiring not only the excision of the offending tumors but also concurrent corrective osteotomies, hemiepiphysiodeses, or limb lengthening procedures to restore normal biomechanical alignment.

Exhaustive Indications and Contraindications

The decision-making process for the surgical intervention of osteochondromas is nuanced, requiring a careful balance between the natural history of the disease and the potential morbidity of surgery. The fundamental philosophy in orthopedic oncology regarding asymptomatic, benign-appearing osteochondromas is one of judicious observation. Routine prophylactic excision of asymptomatic lesions to prevent malignant transformation is universally condemned, given the exceedingly low risk in solitary lesions (<1%) and the inherent risks of surgical intervention. However, when specific clinical or radiographic criteria are met, surgical resection becomes the definitive standard of care.

Absolute indications for the surgical resection of an osteochondroma revolve around the suspicion or confirmation of malignant transformation and severe neurovascular compromise. Any lesion in a skeletally mature patient that exhibits new-onset growth, unexplained pain, or a cartilage cap exceeding 1.5 cm on MRI must be treated as a secondary chondrosarcoma until proven otherwise. In these cases, the surgical approach shifts from a simple marginal excision to a wide en bloc resection to ensure negative oncologic margins. Similarly, if an osteochondroma causes acute vascular compromise (e.g., pseudoaneurysm, ischemia) or progressive motor neuropathy (e.g., progressive foot drop from common peroneal nerve compression), urgent surgical decompression and tumor excision are absolutely indicated to prevent irreversible tissue damage.

Relative indications encompass a broader spectrum of clinical presentations where the lesion causes significant functional impairment or mechanical symptoms. Chronic pain due to recurrent bursitis or direct mechanical irritation of overlying tendons (such as snapping of the pes anserinus or iliotibial band) is a common and valid indication for excision. Joint impingement that physically restricts the range of motion, particularly in the hip or shoulder, also warrants surgical intervention to restore normal biomechanics. In the pediatric population with MHE, relative indications include the prevention or correction of progressive skeletal deformities. Excision of a lesion that is actively tethering growth or causing an angular deformity may be performed in conjunction with corrective osteotomies, though the timing must be carefully calculated to minimize the risk of recurrence while maximizing the remaining growth potential.

Contraindications to surgical intervention are primarily centered around asymptomatic lesions and patient-specific risk factors. The most notable contraindication is the excision of an asymptomatic osteochondroma in a growing child. Because the lesion arises from the physis, surgical excision carries a significant risk of iatrogenic physeal injury, which can lead to premature growth arrest and subsequent limb length discrepancy or angular deformity. Furthermore, the recurrence rate is substantially higher if the lesion is excised before skeletal maturity. General medical contraindications, such as severe cardiopulmonary comorbidities that preclude safe anesthesia, or active local infections overlying the surgical site, also apply.

Indications and Contraindications Summary

Pre-Operative Planning, Templating, and Patient Positioning

Thorough pre-operative planning is the bedrock of successful orthopedic oncology surgery, and the management of osteochondromas is no exception. The planning phase begins with an exhaustive radiographic evaluation. High-quality, orthogonal plain radiographs are the initial modality of choice and are often diagnostic. The surgeon must scrutinize the films to confirm medullary continuity, assess the base of the lesion (pedunculated vs. sessile), and evaluate for any suspicious features such as intralesional calcifications resembling "rings and arcs" (suggestive of chondroid matrix) or cortical destruction. For lesions located in anatomically complex regions such as the pelvis, scapula, or spine, a computed tomography (CT) scan with 3D reconstruction is invaluable for defining the osseous anatomy and planning the osteotomy planes.

Magnetic Resonance Imaging (MRI) is the gold standard for evaluating the soft tissue envelope and the cartilage cap. An MRI with and without intravenous contrast is mandatory if there is any clinical suspicion of malignant transformation. The surgeon must meticulously measure the maximum thickness of the cartilage cap on T2-weighted sequences. Furthermore, the MRI allows for the precise mapping of adjacent neurovascular structures. For example, in a distal medial femoral osteochondroma, the MRI will clearly delineate the relationship between the cartilaginous cap and the superficial femoral artery. If the imaging suggests vascular tethering or pseudoaneurysm, a pre-operative CT angiogram or formal conventional angiogram should be obtained, and the presence of a vascular surgeon on standby during the procedure may be required.

Pre-operative templating involves determining the exact site and angle of the planned osteotomy. The surgical goal for a benign osteochondroma is an extracapsular marginal excision. The surgeon must template the cut to occur at the base of the stalk, flush with the normal cortical contour of the host bone. Leaving a residual stump increases the risk of recurrence, while an overly aggressive cut into the medullary canal creates a significant stress riser, predisposing the patient to a postoperative pathologic fracture. In cases of large sessile lesions where a massive cortical defect is anticipated, the surgeon must template for potential prophylactic internal fixation (e.g., a locking plate) or the use of bone graft substitutes to restore structural integrity.

Patient positioning is dictated entirely by the anatomical location of the lesion and the required surgical approach. For the most common lesions around the knee (distal femur and proximal tibia), the patient is typically positioned supine on a radiolucent table. A bump may be placed under the ipsilateral hip to internally rotate the leg for lateral lesions, or the leg may be placed in a "figure-of-four" position for medial lesions. A sterile tourniquet is universally applied but should only be inflated after exsanguination to minimize intraoperative bleeding and optimize visualization of the tumor capsule. For posterior lesions of the distal femur or proximal tibia, the patient must be positioned prone. Regardless of the position, the entire extremity must be prepped and draped free to allow for intraoperative manipulation, and fluoroscopy (C-arm) must be readily available and positioned to allow for orthogonal views of the surgical site without compromising the sterile field.

Step-by-Step Surgical Approach and Resection Technique

The surgical approach to an osteochondroma must be meticulously executed to ensure complete removal of the lesion while minimizing morbidity to surrounding tissues. The incision is planned longitudinally over the most prominent aspect of the mass, allowing for extensile exposure if necessary. In oncologic surgery, even for presumed benign lesions, the approach should avoid transverse incisions that cross multiple anatomic compartments. Once the skin and subcutaneous tissues are incised, the surgeon performs a blunt dissection down to the muscular layer. Rather than transecting muscle bellies, the approach should exploit internervous and intermuscular planes. The muscle fibers overlying the exostosis are longitudinally split and retracted to expose the underlying tumor mass and its associated bursa.

Management of the exostosis bursa and the tumor pseudocapsule is a critical step. The bursa, which may be thickened and fluid-filled, should be carefully incised and evaluated. If there is any suspicion of malignancy, the bursa and the overlying pseudocapsule must be kept intact, and the dissection must proceed outside this envelope to achieve a marginal or wide resection. For definitively benign lesions, the bursa can be excised to expose the glistening, bluish-white hyaline cartilage cap. At this juncture, meticulous identification and protection of adjacent neurovascular structures are mandatory. For instance, when approaching a proximal fibular osteochondroma, the common peroneal nerve must be identified proximally, neurolysed, and gently retracted with a vessel loop before any bone work commences.

The osteotomy is the defining moment of the procedure. The goal is to resect the lesion flush with the normal cortex of the host bone. The periosteum at the base of the stalk is incised circumferentially. Using a combination of curved osteotomes, gouges, or an oscillating saw, the surgeon begins the cut at the base of the exostosis. It is imperative to direct the osteotome away from the joint and away from critical neurovascular structures. The cut must encompass the entire base to ensure that no cartilage cap or perichondrium is left behind, as retained perichondrium is the primary etiology of local recurrence. Once the lesion is freed, it is passed off the field en bloc for definitive histopathological analysis to rule out microscopic foci of malignant transformation.

Following the removal of the tumor, the host bone defect is carefully managed. The exposed medullary canal is often a source of significant cancellous bleeding. This is meticulously controlled using bone wax, bipolar electrocautery, or topical hemostatic agents (e.g., Gelfoam or Surgicel). The surgeon must then evaluate the structural integrity of the remaining bone. If the resection of a large sessile lesion has resulted in a cortical defect exceeding 30-50% of the bone's diameter, prophylactic internal fixation with a dynamic compression plate or locking plate may be indicated to prevent a postoperative stress fracture. The wound is thoroughly irrigated with pulsatile lavage to remove any microscopic cartilaginous debris. A deep subfascial drain is routinely placed to prevent hematoma formation, and the wound is closed in multiple layers, ensuring a watertight fascial closure to optimize soft tissue healing.

Complications, Incidence Rates, and Salvage Management

While the excision of a solitary osteochondroma is generally considered a low-risk orthopedic procedure, complications can and do occur, occasionally leading to significant patient morbidity. The most frustrating complication for both the patient and the surgeon is local recurrence. The incidence of recurrence following surgical excision is approximately 2% for solitary lesions but can be significantly higher in patients with MHE or in pediatric patients who undergo excision prior to skeletal maturity. Recurrence is almost exclusively iatrogenic, resulting from the incomplete surgical removal of the cartilage cap or the overlying perichondrial ring. Salvage management for a symptomatic recurrence involves a revision marginal excision, requiring a more extensile approach due to altered surgical planes and postoperative scarring.

Neurovascular injury represents the most devastating acute complication. The incidence varies wildly based on the anatomical location of the tumor but is highest in lesions of the proximal fibula, distal medial femur, and proximal humerus. Iatrogenic transection or traction neuropraxia of the common peroneal nerve during proximal fibular resections can result in a permanent foot drop. Vascular injuries, including partial lacerations of the superficial femoral artery or popliteal vessels, can lead to limb-threatening ischemia or delayed pseudoaneurysm formation. Salvage management of a nerve transection requires immediate microsurgical primary repair or nerve grafting. Vascular injuries demand immediate intraoperative consultation with a vascular surgeon for primary repair, vein grafting, or bypass.

Fracture through the surgical resection site is a significant biomechanical complication, particularly following the excision of large, broad-based sessile osteochondromas. The cortical defect acts as a massive stress riser. The incidence of postoperative fracture is estimated at 1-3%. These fractures typically occur within the first 6 weeks postoperatively, often due to premature return to unprotected weight-bearing or athletic activities. Salvage management depends on the fracture pattern and location but generally requires formal open reduction and internal fixation (ORIF) with robust plating constructs, and potentially autologous bone grafting to fill the residual void and promote union.

Postoperative hematoma and subsequent surgical site infection (SSI) are inherent risks of any orthopedic oncologic procedure. The highly vascular medullary bone exposed during the osteotomy can bleed insidiously after the tourniquet is deflated. A large, expanding hematoma can cause severe pain, wound dehiscence, and acts as an ideal culture medium for bacteria. The incidence of SSI following osteochondroma excision is roughly 1-2%. Superficial infections can often be managed with targeted oral antibiotics. However, deep space infections or infected hematomas require urgent formal surgical irrigation and debridement (I&D), followed by culture-directed intravenous antibiotic therapy.

Complications and Salvage Management Summary

Phased Post-Operative Rehabilitation Protocols

The postoperative rehabilitation protocol following the excision of an osteochondroma is highly individualized, heavily dependent on the anatomical location of the lesion, the size of the resultant cortical defect, and whether any concomitant reconstructive procedures were performed. However, a structured, phased approach is essential to optimize functional recovery while protecting the surgical site from catastrophic failure. Phase I (0 to 2 weeks postoperatively) is the immediate tissue healing phase. The primary goals are pain control, edema management, and protection of the osteotomy site. For standard pedunculated lesions of the lower extremity, patients are typically allowed weight-bearing as tolerated (WBAT) with the assistance of crutches. However, if a large sessile lesion was excised, creating a significant stress riser, the patient may be restricted to touch-down weight-bearing (TDWB) or non-weight-bearing (NWB) for up to 4-6 weeks. Gentle, passive, and active-assisted range of motion (ROM) exercises of the adjacent joints are initiated immediately to prevent capsular adhesions and stiffness.

Phase II (2 to 6 weeks postoperatively) focuses on restoring full, uninhibited range of motion and initiating early muscular strengthening. Once the surgical incision has completely healed and sutures or staples are removed (typically at 14 days), patients can begin more aggressive physical therapy. The emphasis shifts to the specific muscle groups that were manipulated during the surgical exposure. For example, following a distal medial femoral excision, targeted strengthening of the vastus medialis obliquus (VMO) and the adductor complex is prioritized. Closed-kinetic chain exercises, stationary bicycling, and aquatic therapy are excellent modalities during this phase, as they provide resistance while minimizing impact forces across the healing bone.

Phase III (6 to 12 weeks postoperatively) is the advanced strengthening and functional training phase. Progression to this phase requires radiographic evidence of early bone remodeling and cortical healing at the resection site, confirmed via plain radiographs. Patients transition to full, unassisted weight-bearing if they have not already done so. The rehabilitation program becomes more rigorous, incorporating open-kinetic chain exercises, progressive resistance training, and intensive proprioceptive drills. Balance boards, single-leg squats, and dynamic stabilization exercises are utilized to restore neuromuscular control. The therapist must closely monitor the patient for any signs of mechanical pain at the osteotomy site, which could indicate micro-motion or impending stress fracture.

The final phase involves the return to play or return to unrestricted high-impact activities. This typically occurs between 3 to 6 months postoperatively. The criteria for full clearance are stringent and non-negotiable. The patient must be entirely pain-free at the surgical site and during maximum exertion. Clinical examination must demonstrate a full, symmetric range of motion and muscular strength that is at least 90% of the contralateral, unaffected limb. Most importantly, follow-up radiographs must demonstrate complete obliteration of the surgical defect with mature, remodeled cortical bone. Premature return to contact sports or high-impact loading before these criteria are met significantly elevates the risk of a devastating postoperative fracture.

Summary of Landmark Literature and Clinical Guidelines

The contemporary understanding and management of osteochondromas and Multiple Hereditary Exostoses are built upon a robust foundation of landmark orthopedic and genetic literature. Historically, the clinical behavior of these lesions was documented through extensive case series, but the paradigm shifted dramatically in the late 1990s with the molecular identification of the EXT1 and EXT2 genes. The seminal work by Ahn et al. and Wuyts et al. elucidated the role of these genes in heparan sulfate biosynthesis, directly linking a specific biochemical defect to the macroscopic development of bone tumors. This discovery not only provided a definitive genetic test for MHE but also opened the door for targeted molecular therapies, which are currently the subject of intense ongoing research.

In the realm of clinical guidelines regarding malignant transformation, the literature is heavily guided by the work of Bernard et al. and Garrison et al., who established the modern radiographic criteria for secondary chondrosarcoma. Their extensive retrospective reviews definitively demonstrated that a cartilage cap thickness exceeding 1.5 cm (and certainly >2.0 cm) on T2-weighted MRI in a skeletally mature patient is the most reliable independent predictor of malignancy. These studies form the basis of the current National Comprehensive Cancer Network (NCCN) and Musculoskeletal Tumor Society (MSTS) guidelines, which mandate advanced imaging and biopsy or wide resection for any lesion meeting these cap thickness criteria, particularly when associated with new-onset pain or growth.

Clinical guidelines for the routine screening and surveillance of patients with MHE have evolved to balance vigilance with resource allocation. The international consensus, supported by the MHE Research Foundation, recommends that children with MHE undergo baseline full-body radiographic surveys to map the extent of the disease. During the growing years, annual clinical examinations focusing on limb alignment, joint range of motion, and neurovascular status are recommended. Routine annual whole-body MRIs are generally not recommended for asymptomatic pediatric patients due to the low risk of malignant transformation in childhood and the high cost. However, once the patient reaches skeletal maturity, a baseline whole-body MRI is increasingly advocated by orthopedic oncologists to establish a baseline cartilage cap thickness for all lesions, facilitating easier comparison if a lesion becomes symptomatic later in life.

Looking toward the future, the literature is increasingly focused on pharmacological interventions to prevent the formation of exostoses in MHE patients. Landmark preclinical studies utilizing mouse models of MHE have demonstrated that retinoic acid receptor gamma (RAR-gamma) agonists, such as palovarotene, can significantly inhibit the formation of osteochondromas by modulating the aberrant chondrocyte differentiation pathways. Current phase II and phase III clinical trials are actively investigating the efficacy and safety of palovarotene